Vindesine is a new vinca alkaloid with broadspectrum antineoplastic activity in experimental
tumor models. Phase-I studies have shown that a weekly dosage regimen of 3–4 mg/m 2 IV …

Vindesine, a newer vinca alkaloid derivative, underwent a phase I clinical evaluation in 68
humans with advanced, refractory malignancies. Patients received single total doses …

SUMMARY A broad phase II study of vindesine was conducted in 79 adults with advanced
malignancies. Most patients had solid tumors, particularly adenocarcinomas (59%), and 67 …

Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. However, its
antineoplastic spectrum more closely resembles that of vincristine. Clinical studies indicate …

Vindesine (VDS) is an analogue of the vinca alkaloids. Its spectrum of antitumoral activity is
similar to that of vincristine (VCR), but with milder experimental neurotoxicity, and it inhibits …

Vindesine, a vinca alkaloid derived from vinblastine, has been examined for activity against
a variety of solid and hematological malignancies. Single-agent response rates average …

SUMMARY A phase I evaluation of vindesine was carried out in 69 adult patients with
advanced malignancies. Two escalating dose schedules were explored:(a) a single dose …

The vinca alkaloids have been found to have activity against a variety of solid tumors,
although they are most active against hematological malignancies. Activity has been …

A good tumoricidal activity of vindesine (VDS) has been reported in a variety of animal
tumors and in human leukemias and lymphomas. We treated 22 patients who had received …

A dose of 3-4 mg/m² of vindesine (DVA) was given by iv push weekly to 33 patients with non-
small cell lung cancer. Twenty-nine patients were evaluable for response. All evaluable …